Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease

The incremental cost-effectiveness ratio for semaglutide compared to standard care was $72,962 per QALY gained.

• Semaglutide is associated with a clinically relevant reduction in body weight and lower risk of adverse cardiovascular events in overweight or obese individuals with a history of cardiovascular disease but no diabetes.
• A decision analytic model was used to estimate the lifetime benefits and costs of semaglutide versus standard care from the health care payer perspective.
• The likelihood of cost-effectiveness for semaglutide increases if the medication price is halved, resulting in an attractive ratio of $37,190 per QALY gained.
• Factors significantly influencing cost-effectiveness include the efficacy of semaglutide on mortality and its overall cost.

AI simplified